- Home
- STTK
STTK
Shattuck Labs Inc.
as 04-23-2025 4:00pm EST
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | AUSTIN |
| Market Cap: | 36.2M | IPO Year: | 2020 |
| Target Price: | $3.00 | AVG Volume (30 days): | 305.5K |
| Analyst Decision: | Hold | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.49 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.69 - $11.76 | Next Earning Date: | 05-01-2025 |
| Revenue: | $5,721,000 | Revenue Growth: | 245.26% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Shattuck Labs Inc. News
STTK Breaking Stock News: Dive into STTK Ticker-Specific Updates for Smart Investing
Simply Wall St.
16 days ago
3 Promising Penny Stocks With Market Caps Under $300M
GlobeNewswire
22 days ago
Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference
Simply Wall St.
a month ago
Shattuck Labs Full Year 2024 Earnings: Misses Expectations
GlobeNewswire
a month ago
Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights
MT Newswires
a month ago
Leerink Partners Initiates Shattuck Labs at Outperform With $4 Price Target
Simply Wall St.
a month ago
Favourable Signals For Shattuck Labs: Numerous Insiders Acquired Stock
GlobeNewswire
2 months ago
Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn’s and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025
GlobeNewswire
2 months ago
Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn’s and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025
Compare STTK vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "STTK Shattuck Labs Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.